A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Détail de l'auteur
Auteur Shane R. Kannarr
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Affiner la rechercheComparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study / Gina Wesley in OVS : Optometry & Vision Science, vol. 99, 04 (Avril 2022)
[article]
in OVS : Optometry & Vision Science > vol. 99, 04 (Avril 2022)
Titre : Comparison of Two Thermal Pulsation Systems in the Treatment of Meibomian Gland Dysfunction: A Randomized, Multicenter Study Type de document : article de périodique Auteurs : Gina Wesley ; Katherine M. Bickle ; Johnathon Downing ; Bret Fisher ; Brennan Greene ; Colton Heinrich ; David Kading ; Shane R. Kannarr ; Jason Miller ; Satish Modi ; David Ludwick ; Joseph Tauber ; Sruthi Srinivasan ; Venkiteshwar Manoj Année de publication : 2022 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Recherche comparative sur l'efficacité
[Thésaurus Mesh]Syndromes de l'oeil sec
[Thésaurus Mesh]ThérapeutiqueMots-clés : Système de pulsations thermiques Résumé : SIGNIFICANCE: Given the significance of meibomian gland dysfunction subjects in evaporative dry eye, its chronic
and progressive nature, limited promising treatment options, and novel treatment techniques are important. This
randomized clinical study evaluated the noninferiority of SYSTANE iLux with LipiFlow in meibomian gland dysfunction treatment at 12 months.
PURPOSE: This study aimed to demonstrate noninferiority of SYSTANE iLux compared with LipiFlow at 12 months
after single treatment in meibomian gland dysfunction subjects with evaporative dry eye.
METHODS: In this prospective, randomized, multicenter, assessor-masked, parallel-group trial, subjects (N = 236;
aged ≥18 years) with meibomian gland score (MGS) of ≤12 in lower eyelids, noninvasive tear breakup time (NITBUT;
first breakup) of <10 seconds, and Impact of Dry Eye on Everyday Life—Symptom Bother (IDEEL-SB) module score
of >16 were randomized (1:1) to receive SYSTANE iLux (n = 119) or LipiFlow (n = 117). Subjects attended a total
of eight visits, including screening, treatment, and follow-up visits at 2 weeks and at 1, 3, 6, 9, and 12 months/
exit, to evaluate change from baseline in MGS, NITBUT, IDEEL-SB module score, and safety outcomes.
RESULTS: A total of 227 subjects completed the study (mean ± standard deviation age, 57.3 ± 13.8 years). At
12 months, least squares mean change from baseline in MGS was similar between iLux and LipiFlow
(17.4 ± 1.97 vs. 17.8 ± 1.98). Noninferiority of SYSTANE iLux compared with LipiFlow in change from baseline
in MGS (95% lower confidence limit of least squares mean difference, >−5), NITBUT (>−2.5 seconds), and
IDEEL-SB score (95% upper confidence limit, <12) was achieved at all post-treatment visits. No other serious ocular or device-related adverse events were reported.
CONCLUSIONS: The treatment outcomes with SYSTANE iLux were noninferior to LipiFlow during the 12-month
follow-up in subjects with dry eye–associated meibomian gland dysfunction.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial / Paul M. Karpecki in OVS : Optometry & Vision Science, vol. 98, 03 (Mars 2021)
[article]
in OVS : Optometry & Vision Science > vol. 98, 03 (Mars 2021)
Titre : Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial Type de document : article de périodique Auteurs : Paul M. Karpecki ; Shane A. Foster ; Stephen M. Montaquila ; Shane R. Kannarr ; Charles B. Slonim ; Alan R. Meyer ; Mina P. Sooch ; Reda M. Jaber ; Konstantinos Charizanis ; Jonah E. Yousif ; Seth A. Klapman ; Arin T. Amin ; Marguerite B. McDonald ; Gerald D. Horn ; Eliot S. Lazar ; Jay S. Pepose Année de publication : 2021 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]:M:Mydriase:Mydriase / thérapie
[Thésaurus Mesh]Mydriase
[Thésaurus Mesh]Phentolamine
[Thésaurus Mesh]Solutions ophtalmiquesRésumé : SIGNIFICANCE: After a dilated eye examination, many patients experience symptoms of prolonged light sensitivity, blurred vision, and cycloplegia associated with pharmacological mydriasis. Phentolamine mesylate ophthalmic
solution (PMOS) may expedite the reversal of mydriasis in patients, potentially facilitating return to functional vision and reducing barriers to obtaining dilated eye examinations.
PURPOSE: The protracted reversal time after pharmacologically induced pupil dilation impairs vision. We tested
the hypothesis that PMOS rapidly reduces pupil diameter in this acute indication.
METHODS: In this double-masked placebo-controlled, randomized, two-arm crossover phase 2b trial, we evaluated
the effects of one drop of 1% PMOS applied bilaterally in subjects who had their pupils dilated by one of two common
mydriatic agents: 2.5% phenylephrine or 1% tropicamide. End points included change in pupil diameter, percent
of subjects returning to baseline pupil diameter, and accommodative function at multiple time points.
RESULTS: Thirty-one subjects completed the study (15 dilated with phenylephrine and 16 with tropicamide).
Change in pupil diameter from baseline at 2 hours after maximal dilation with 1% PMOS was −1.69 mm and
was significantly greater in magnitude compared with placebo for every time point beyond 30 minutes (P < .05).
At 2 hours, a greater percentage of study eyes given 1% PMOS returned to baseline pupil diameter compared with
placebo (29 vs. 13%, P = .03), which was this also seen at 4 hours (P < .001). More subjects treated with PMOS in
the tropicamide subgroup had at least one eye returning to baseline accommodative amplitude at 2 hours (63 vs.
38%, P = .01). There were no severe adverse events, with only mild to moderate conjunctival hyperemia that resolved in most patients by 6 hours.
CONCLUSIONS: Phentolamine mesylate ophthalmic solution at 1% reversed medically induced pupil dilation
more rapidly than placebo treatment regardless of which mydriatic was used (adrenergic agonists and cholinergic
blockers) with a tolerable safety profile.Note de contenu :
Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire